Dake Benjamin T. - 06 Sep 2022 Form 4 Insider Report for Aerovate Therapeutics, Inc. (JBIO)

Role
Officer Title: President, Chief Operating Officer and Secretary
Signature
/s/ George A. Eldridge, Attorney-in-Fact
Issuer symbol
JBIO
Transactions as of
06 Sep 2022
Net transactions value
-$207,093
Form type
4
Filing time
08 Sep 2022, 17:30:34 UTC
Previous filing
18 Aug 2022
Next filing
12 Sep 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AVTE Common Stock Options Exercise $15,949 +9,166 $1.74* 9,166 06 Sep 2022 Direct F1
transaction AVTE Common Stock Sale $79,345 -4,422 -48% $17.94 4,744 06 Sep 2022 Direct F1, F2
transaction AVTE Common Stock Sale $78,546 -4,138 -87% $18.98 606 06 Sep 2022 Direct F1, F3
transaction AVTE Common Stock Sale $11,984 -606 -100% $19.78 0 06 Sep 2022 Direct F1, F4
transaction AVTE Common Stock Options Exercise $14,303 +8,220 $1.74* 8,220 07 Sep 2022 Direct F1
transaction AVTE Common Stock Sale $82.65 -5 -0.12% $18.12 3,658 07 Sep 2022 Direct F1, F5
transaction AVTE Common Stock Sale $67,386 -3,658 -100% $18.42 0 07 Sep 2022 Direct F1, F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVTE Stock Option (Right to Buy) Options Exercise $0 -9,166 -17% $0.000000 45,348 06 Sep 2022 Common Stock 9,166 $1.74 Direct F1, F7
transaction AVTE Stock Option (Right to Buy) Options Exercise $0 -8,220 -18% $0.000000 37,128 07 Sep 2022 Common Stock 8,220 $1.74 Direct F1, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.56 to $18.50, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.57 to $19.50, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.595 to $20.075, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F5 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.32 to $18.32, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F6 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.345 to $18.625, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F7 A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Remarks:

Officer Title: President, Chief Operating Officer and Secretary